Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Javier Torres

Internal Medicine Mayaguez, PR Medical Doctor

NPI 1063935039 CMS profile 7453825

Plaza Yaguez 114 Calle De La Candelaria, Mayaguez, PR 00680

Open in the dashboard

General payments

$10,107

223 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Javier Torres of Mayaguez, PR is reported in the CMS Open Payments database as having received $10,107 across 223 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,173 71
2024 General $3,158 65
2023 General $1,310 26
2022 General $1,857 33
2021 General $443 19
2020 General $165 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Javier Torres
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Javier Torres were reported at $3,173. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Javier Torres Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $165 $119 $33–$402 $114
2021 $443 $135 $37–$521 $132
2022 $1,857 $141 $42–$496 $149
2023 $1,310 $149 $45–$519 $160
2024 $3,158 $154 $47–$537 $164
2025 $3,173 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $2,742 61 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,186 29 payments
  3. United Therapeutics Corporation $1,040 11 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $679 8 payments
  5. Boston Scientific Corporation $600 11 payments
  6. Janssen Pharmaceuticals, Inc $509 21 payments
  7. GlaxoSmithKline, LLC. $381 9 payments
  8. Jazz Pharmaceuticals Inc. $352 7 payments
  9. Merck Sharp & Dohme Corporation $305 10 payments
  10. Genzyme Corporation $303 9 payments
  11. Other $2,010 47 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $9,806 219 payments
  2. Education $301 4 payments
Products named General payments · program years 2020–2025
  1. TEZSPIRE $1,045 16 payments
  2. FASENRA $942 27 payments
  3. OFEV Respiratory $547 17 payments
  4. DUPIXENT $487 11 payments
  5. XARELTO $384 16 payments
  6. AIRSUPRA $353 6 payments
  7. XYWAV $352 7 payments
  8. UPTRAVI $326 7 payments
  9. TYVASO $318 4 payments
  10. OFEV Respiratory $311 5 payments
  11. Other $4,820 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

50

Median for General Practice: 1,105

Drug cost

$151,170

Median for General Practice: $48,734

Branded share of claims

72%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 11 $143,173
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $7,314
Albuterol Sulfate Hfa Albuterol Sulfate Brand 14 $599
Montelukast Sodium Generic 14 $84

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $494
  • Amgen Inc. $103
$597 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $457
$457 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $275
$275 11 —
DUPIXENT
  • GENZYME CORPORATION $151
  • SANOFI-AVENTIS U.S. LLC $95
$246 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $173
$173 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

223 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record